Physician profile
Joel Silverman
NPI 1366462863
$12,726.36
in general payments reported to CMS, 2019-2025
26 companies · $2,502 in 2025
The $2,502 reported for 2025 was more than what 80% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,155 · 2020: $1,273 · 2021: $1,346 · 2022: $2,004 · 2023: $2,482 · 2024: $1,965 · 2025: $2,502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,733 · Education: $216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,732.60 |
| Education | $216.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,912.30 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $2,262.67 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,854.50 | 2019-2025 | Ofev, Jascayd |
| Insmed, INC. | $864.98 | 2019-2025 | Arikayce |
| Actelion Pharmaceuticals US, INC. | $714.91 | 2019-2025 | Opsumit, Uptravi |
| Genzyme Corporation | $534.20 | 2021-2025 | |
| Advanced Respiratory, INC | $489.27 | 2019-2021 | |
| Philips North America LLC | $455.60 | 2019-2023 | |
| Electromed, INC. | $443.45 | 2021-2025 | Smartvest |
| Amgen INC. | $421.21 | 2022-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $365.40 | 2019-2024 | Dupixent |
| Mylan Specialty L.P. | $249.97 | 2019-2024 | Yupelri |
| Verona Pharma, INC. | $233.96 | 2025 | Ohtuvayre |
| Mallinckrodt Hospital Products INC. | $232.82 | 2020-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $203.51 | 2019-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inogen, INC. | $155.08 | 2022-2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Baxter Healthcare | $73.84 | 2022-2024 | Hillrom - Vest System Model 105 Home Care |
| Teva Pharmaceuticals USA, INC. | $57.53 | 2019-2022 | |
| Genentech USA, INC. | $38.76 | 2019 | |
| Viatris Specialty LLC | $33.92 | 2025 | Yupelri |
| United Therapeutics Corporation | $32.15 | 2024-2025 | Tyvaso, Tyvaso |
| Takeda Pharmaceuticals U.S.A., INC. | $26.69 | 2022 | |
| Grifols USA, LLC | $19.63 | 2022 | |
| Pfizer INC. | $18.76 | 2019 | |
| Ani Pharmaceuticals, INC. | $17.01 | 2025 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $14.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Silverman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.